ADMA - ADMA Biologics GAAP EPS of -$0.13 misses by $0.04 revenue of $29.1M beats by $0.95M

ADMA Biologics press release (NASDAQ:ADMA): Q1 GAAP EPS of -$0.13 misses by $0.04. Revenue of $29.1M (+81.8% Y/Y) beats by $0.95M. Gross profit for the first quarter of 2022 was $3.7 million, compared to a gross loss of $1.7 million for the first quarter of 2021. Enabled by the strong start to the year, ADMA increases 2022 total revenue guidance to $130 million or more, upwardly revised from $125 million. ADMA reiterates expectations to grow revenues and gross profits and narrow net losses as 2022 progresses. 2024-2025 Financial Guidance: We believe that ADMA is on track to potentially generate $250 million in topline revenue in 2024, and $300 million thereafter. At this revenue level, and based upon current assumptions, we anticipate potentially achieving 40-50% corporate gross margins and 20-30% net income margins. These assumptions translate to potential annual gross profit and net income of $100-150 million and $50-100 million respectively

For further details see:

ADMA Biologics GAAP EPS of -$0.13 misses by $0.04, revenue of $29.1M beats by $0.95M